

Institutional review board statement

ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via up-regulation of p53 and down-regulation of PNCA

Xin-Fang Hou¹, Lin-Ping Xu², Hai-Yan Song³, Shuai Li¹, Chen Wu¹, Ju-Feng Wang¹

1. Department of Medical oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 2. Department of Science and Research, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 3. Key Laboratory for Medical Tissue Regeneration of Henan Province, College of Basic Medicine, Xinxiang Medical University, Xinxiang, China

The study was carried out in accordance with a protocol approved by the Ethics Committee of Henan Cancer Hospital (Henan, China).

Ju-feng wang.

Ju-Feng Wang, MD, Professor,
Department of Medical oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou 450008, China.

Email: 13783583966@163.com

Telephone: +86-371-65587598

Fax: +86-371-65587598